Ingevity Corp (NGVT) stock
NGVTNYSEChemicals & Allied ProductsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3076% above fair value
$58.31−0.97 (-1.64%)
Close on Nov 18, 2026Market cap $2.00BP/E 39.7Yield –
Ingevity revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Ingevity's revenue for the twelve months ending Jun 30, 2026 was $1.16B, down 1.4% year over year. For fiscal 2025 it was $1.17B, down 2.7% from the year before. Over ten years it grew 2.0% a year on average. The highest annual figure on record is $1.67B in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.17B | -2.7% |
| FY2024 | Dec 31, 2024 | $1.20B | -1.3% |
| FY2023 | Dec 31, 2023 | $1.22B | -27.1% |
| FY2022 | Dec 31, 2022 | $1.67B | +19.9% |
| FY2021 | Dec 31, 2021 | $1.39B | +14.4% |
| FY2020 | Dec 31, 2020 | $1.22B | -5.9% |
| FY2019 | Dec 31, 2019 | $1.29B | +14.1% |
| FY2018 | Dec 31, 2018 | $1.13B | +16.6% |
| FY2017 | Dec 31, 2017 | $972.40M | +7.1% |
| FY2016 | Dec 31, 2016 | $908.30M | -5.2% |
| FY2015 | Dec 31, 2015 | $958.30M | -7.5% |
| FY2014 | Dec 31, 2014 | $1.04B | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $314.10M | -5.2% |
| Q1 FY2026 | Mar 31, 2026 | $258.00M | +4.1% |
| Q4 FY2025 | Dec 31, 2025 | $255.10M | -3.1% |
| Q3 FY2025 | Sep 30, 2025 | $333.10M | -0.2% |
| Q2 FY2025 | Jun 30, 2025 | $331.50M | -15.1% |
| Q1 FY2025 | Mar 31, 2025 | $247.90M | -27.1% |
| Q4 FY2024 | Dec 31, 2024 | $263.30M | -29.2% |
| Q3 FY2024 | Sep 30, 2024 | $333.80M | -25.2% |
| Q2 FY2024 | Jun 30, 2024 | $390.60M | -18.9% |
| Q1 FY2024 | Mar 31, 2024 | $340.10M | -13.4% |
| Q4 FY2023 | Dec 31, 2023 | $371.70M | -3.1% |
| Q3 FY2023 | Sep 30, 2023 | $446.00M | -7.5% |
| Q2 FY2023 | Jun 30, 2023 | $481.80M | +14.7% |
| Q1 FY2023 | Mar 31, 2023 | $392.60M | +2.6% |
| Q4 FY2022 | Dec 31, 2022 | $383.60M | +14.2% |
| Q3 FY2022 | Sep 30, 2022 | $482.00M | +27.9% |
| Q2 FY2022 | Jun 30, 2022 | $419.90M | +17.2% |
| Q1 FY2022 | Mar 31, 2022 | $382.80M | +19.5% |
| Q4 FY2021 | Dec 31, 2021 | $336.00M | +3.2% |
| Q3 FY2021 | Sep 30, 2021 | $376.80M | +13.6% |
| Q2 FY2021 | Jun 30, 2021 | $358.40M | +32.4% |
| Q1 FY2021 | Mar 31, 2021 | $320.30M | +11.1% |
| Q4 FY2020 | Dec 31, 2020 | $325.60M | +7.3% |
| Q3 FY2020 | Sep 30, 2020 | $331.70M | -7.8% |
| Q2 FY2020 | Jun 30, 2020 | $270.60M | -23.3% |
| Q1 FY2020 | Mar 31, 2020 | $288.20M | +4.1% |
| Q4 FY2019 | Dec 31, 2019 | $303.40M | +8.9% |
| Q3 FY2019 | Sep 30, 2019 | $359.90M | +15.6% |
| Q2 FY2019 | Jun 30, 2019 | $352.80M | +14.3% |
| Q1 FY2019 | Mar 31, 2019 | $276.80M | +17.7% |
| Q4 FY2018 | Dec 31, 2018 | $278.60M | +21.4% |
| Q3 FY2018 | Sep 30, 2018 | $311.20M | +17.8% |
| Q2 FY2018 | Jun 30, 2018 | $308.60M | +18.6% |
| Q1 FY2018 | Mar 31, 2018 | $235.20M | +7.6% |
| Q4 FY2017 | Dec 31, 2017 | $229.50M | +8.8% |
| Q3 FY2017 | Sep 30, 2017 | $264.10M | +4.6% |
| Q2 FY2017 | Jun 30, 2017 | $260.30M | – |
| Q1 FY2017 | Mar 31, 2017 | $218.50M | – |
| Q4 FY2016 | Dec 31, 2016 | $210.90M | – |
| Q3 FY2016 | Sep 30, 2016 | $252.40M | – |
See a number that looks wrong?